Is Cell Point overvalued or undervalued?

As of 31 October 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in its market perception. The company appears to be overvalued at this time. Key ratios highlight this concern, with a PE Ratio of 90.66, an EV to EBIT of 17.65, and an EV to EBITDA of 9.87, all suggesting that the stock is trading at a premium compared to its earnings and operational performance.
In comparison to its peers, Cell Point's valuation stands out unfavorably; for instance, PTC India is rated as very attractive with a PE Ratio of 8.02, while Optiemus Infra is considered fair with a PE of 78.3. The stark contrast in these ratios emphasizes Cell Point's overvaluation. Additionally, the company's recent stock performance has been disappointing, with a year-to-date return of -32.9%, significantly underperforming the Sensex, which has returned 8.79% in the same period.